Metagenomi, an Emeryville, Calif.-based gene editing startup, closed a $175 million Series B round led by PFM Health Sciences and Farallon Capital Management. Additional new investors Eventide Asset Management, Deep Track Capital, Frazier Life Sciences, Pura Vida Investments, Irving Investors, Millennium Management, Surveyor Capital, Marshall Wace, Novo Holdings and Bristol Myers Squibb also contributed to the funding, along with previous backers RA Capital Management, Leaps by Bayer and Humboldt Fund. Santhosh Palani, partner at PFM Health Sciences, joined the Metagenomi board.
Patient 21, a Berlin-based digital primary care platform, emerged from stealth with a $142 million investment. Target Global Management led the round, which included participation from Eight Roads, Piton Capital, Pico Capital and Kingsway Capital.
Leyden Laboratories BV, an Amsterdam-based startup developing intranasal products that protect against a broad range of respiratory viruses, completed a $140 million Series B round led by Casdin Capital and GV. Additional existing backers F-Prime Capital and Byers Capital also participated in the new funding, along with new investors SoftBank Vision Fund 2, Invus and Bluebird Ventures. Eli Casdin of Casdin Capital will join Leyden’s board.
Athletic Greens, which sells daily nutrition products including its AG1 nutrition drink, scored a $115 million investment, at a valuation of more than $1 billion. Alpha Wave Global led the round, which included participation from SC.Holdings, Bolt Ventures and others. Mark Vadon, founder of Zulily and Blue Nile, also invested in the round and joined the company’s board alongside Rick Gerson, chairman at Alpha Wave Global.
Distalmotion, a Switzerland-based surgical robot maker, secured $90 million in Series E financing. Led by Revival Healthcare Capital, the round included participation from 415 Capital and others. Revival Chairman Rick Anderson will join the Distalmotion board as chairman.
Kyverna Therapeutics Inc., an Emeryville, Calif.-based cell therapy company engineering a new class of treatments for serious autoimmune diseases, closed an oversubscribed $85 million Series B round. Northpond Ventures led the investment, with Director Shaan Gandhi joining the board. Additional investors in the funding included Westlake Village BioPartners, Vida Ventures, Gilead Sciences, RTW Investments, Insight Partners, LYFE Capital, Intellia Therapeutics and jVen Capital.
Cellino Biotech Inc., a Cambridge, Mass.-based stem-cell therapy startup, scored $80 million in Series A financing. Lead investors Leaps by Bayer, 8VC and Humboldt Fund were joined by Felicis Ventures, The Engine, Khosla Ventures and others in the round.
BenchSci, a Toronto-based startup using machine-learning applications for novel medicine development, nabbed 63 million Canadian dollars ($50 million) in Series C funding led by Inovia Capital and TCV.
Resilience, a French startup specializing in remote monitoring and therapeutic follow-up of cancer patients, landed €40 million ($45 million) in Series A funding. Cathay Innovation led the round, which saw participation from Singular, Exor Seeds, Picus Capital, Seaya Ventures, Vivalto Ventures and others.
Atlas Health, a Seattle-based provider of philanthropic medical financial aid, picked up a $40 million Series A round. Felicis Ventures led the funding, which included support from GreatPoint Ventures, Tribe Capital, Global Founders Capital and MBX Capital.
Infermedica, a preliminary diagnosis and patient triage startup with offices in Poland and Denver, grabbed $30 million in Series B funding. One Peak Partners led the round, with additional support from Karma Ventures, European Bank for Reconstruction and Development, Heal Capital and Inovo Venture Partners.
Sollis Health, a New York-based medical concierge, snagged $30 million in Series A funding. Lead investors Torch Capital and Denali Growth Partners were joined by Strand Equity, Read Capital and others in the round.
|